Close Menu

NEW YORK (GenomeWeb) – Roche today announced it is set to become the majority shareholder of Foundation Medicine following the preliminary results of the closing of its tender offer at the end of the day on Monday.

Under the tender offer, announced in January, Roche proposed to purchase approximately 15.6 million shares of common stock of Foundation Medicine for $50 per share, for an aggregate value of around $780 million. The offer expired at midnight EDT Monday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.